MAPIC-3 Versus High-Throught Trial Population

PIPO was another RCP that randomized patients with acute sub-mass of PE to heparin versus heparin plus weight-based to neck to place. Patients enrolled in the study had both evidence of right heart strain and biomarker positivity. This is compared to MAPIC-3, which had only around 30% of patients in each arm with fine means of RB dysfunction. And so I think as an individual, yes, the mortality was no different, but the intervention rate, which is a kind of a surrogate market, which is what clinically we'll do.